exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275501 RNA Name: hsa-miR-302b-3p RNA Type: miRNA Chromosome: chr4 Starnd: - Coordinate: Start Site(bp): 112648489 End Site(bp): 112648511 External Links: hsa-miR-302b-3p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand RPP14 chr3 58306247 58324695 + SWSAP1 chr19 11374666 11376951 + GPBP1 chr5 57173948 57264679 + C18orf21 chr18 35972625 35979286 + PXYLP1 chr3 141228726 141367753 + ALG5 chr13 36949738 37000261 - SERINC1 chr6 122443351 122471807 - RGMA chr15 93035273 93089204 - CLCN6 chr1 11806096 11848079 + KCTD10 chr12 109448655 109477359 - PLS3 chrX 115561174 115650861 + RPLP1 chr15 69452814 69456205 + DNAJB6 chr7 157335381 157417439 + SYAP1 chrX 16719612 16765340 + RNF149 chr2 101271219 101308701 - SLC35G1 chr10 93893973 93956062 + MSL1 chr17 40121971 40136917 + SND1 chr7 127652194 128092609 + WASF3 chr13 26557683 26688948 + CTR9 chr11 10751246 10801625 + HMGCS1 chr5 43287470 43313512 - CDK6 chr7 92604921 92836594 - WDR37 chr10 1049538 1132384 + ATP6V1B2 chr8 20197381 20226819 + CTSC chr11 88293592 88337761 - HSPA9 chr5 138553756 138575416 - ZNF281 chr1 200404940 200410056 - CELF2 chr10 10798397 11336675 + TNRC6A chr16 24610209 24827632 + ATP13A2 chr1 16985958 17011928 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC011503.2 chr19 23927788 23929287 + AC021078.1 chr5 149494314 149504670 - AC125257.1 chr17 41848518 41851447 - AL049840.4 chr14 103694516 103695050 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - FGD5-AS1 chr3 14920347 14948424 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.